BAFF/BLyS Proteins, Antibodies, cDNA Clones Research Reagents

TNFSF13B (TNF Superfamily Member 13b) is a protein coding gene located on human chromosome 13q33.3. TNFSF13B is also known as DTL, BAFF, BLYS, CD257, TALL1, THANK, ZTNF4, TALL-1, TNLG7A and TNFSF20. The human TNFSF13B gene encodes a 31223 Da protein containing 285 amino acids. The TNFSF13B protein is broadly expressed in appendix, lymph node and other tissues. Among its related pathways are NF-KappaB Family Pathway and PEDF Induced Signaling. TNFSF13B is related to signaling receptor binding and tumor necrosis factor receptor binding. TNFSF12-TNFSF13 is an important paralog of TNFSF13B gene. TNFSF13B is associated with some diseases, including Sialadenitis and Sjogren Syndrome.

BAFF/BLyS Protein (6)

    BAFF/BLyS Antibody (6)

      BAFF/BLyS cDNA Clone (40)


      In cloning vector


      BAFF/BLyS Lysate (4)

        More Product Popular With Customers

        BAFF/BLyS Background

        B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is a single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors are a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS is an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.

        BAFF/BLyS References

        • Nardelli B, et al. (2002) B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk Lymphoma. 43(7): 1367-73.
        • Stohl W. (2006) Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 6(4): 51-8.
        • Cancro MP, et al. (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 119(5): 1066-73.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.